{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T19:13:56Z","timestamp":1783710836369,"version":"3.55.0"},"reference-count":24,"publisher":"Xia & He Publishing","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,28]]},"DOI":"10.14218\/jcth.2020.00039","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T23:25:48Z","timestamp":1602285948000},"page":"1-8","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B"],"prefix":"10.14218","volume":"8","author":[{"given":"Joseph K","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Y","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atif","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrado M","family":"Fernandez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mete","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Noonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Colombato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"key20201009232541_b1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.24804","article-title":"Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin","volume":"56","author":"Kowdley","year":"2012","journal-title":"Hepatology"},{"key":"key20201009232541_b2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"key20201009232541_b3","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"key20201009232541_b4","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"key20201009232541_b5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"key20201009232541_b6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10238-016-0420-7","article-title":"Telbivudine versus lamivudine and entecavir for treatment-na\u00efve decompensated hepatitis B virus-related cirrhosis","volume":"17","author":"Yue-Meng","year":"2017","journal-title":"Clin Exp Med"},{"key":"key20201009232541_b7","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1053\/j.gastro.2006.04.007","article-title":"Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B","volume":"130","author":"Sherman","year":"2006","journal-title":"Gastroenterology"},{"key":"key20201009232541_b8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"key20201009232541_b9","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"key20201009232541_b10","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"key20201009232541_b11","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B","volume":"66","author":"Papatheodoridis","year":"2017","journal-title":"Hepatology"},{"key":"key20201009232541_b12","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"key20201009232541_b13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"key20201009232541_b14","unstructured":"Baraclude\u00ae (entecavir) USPrescribing Information. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_baraclude.pdf"},{"key":"key20201009232541_b15","first-page":"12A","article-title":"Prospective, randomized assessment of HBV-associated and other clinical outcome events during long-term therapy with entecavir or other HBV nucleos(t)ide analogues in patients with chronic HBV infection","volume":"66","author":"Hou","year":"2017","journal-title":"Hepatology"},{"key":"key20201009232541_b16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/jvh.12115","article-title":"Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a \u2018real-world\u2019 clinical practice setting in China","volume":"20","author":"Hou","year":"2013","journal-title":"J Viral Hepat"},{"key":"key20201009232541_b17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ahj.2017.05.010","article-title":"Clinical event adjudication in cardiovascular device trials: An Food and Drug Administration perspective","volume":"191","author":"Farb","year":"2017","journal-title":"Am Heart J"},{"key":"key20201009232541_b18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/CVM-2-4-180","article-title":"Systematic adjudication of myocardial infarction end-points in an international clinical trial","volume":"2","author":"Mahaffey","year":"2001","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"key20201009232541_b19","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jacc.2014.01.038","article-title":"Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial","volume":"63","author":"Mahaffey","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key20201009232541_b20","doi-asserted-by":"crossref","first-page":"e003114","DOI":"10.1161\/CIRCINTERVENTIONS.115.003114","article-title":"Lack of concordance between local investigators, angiographic core laboratory, and clinical event committee in the assessment of stent thrombosis: Results from the TRACER angiographic substudy","volume":"9","author":"Popma","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"key20201009232541_b21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ahj.2017.05.009","article-title":"Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium","volume":"190","author":"Seltzer","year":"2017","journal-title":"Am Heart J"},{"key":"key20201009232541_b22","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"key20201009232541_b23","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"key20201009232541_b24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cgh.2019.07.010","article-title":"Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries","volume":"18","author":"Hou","year":"2020","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Clinical and Translational Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2020-00039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:19:23Z","timestamp":1783707563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2020-00039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,10,10]]},"published-print":{"date-parts":[[2020,12,28]]}},"alternative-id":["10.14218\/JCTH.2020.00039"],"URL":"https:\/\/doi.org\/10.14218\/jcth.2020.00039","relation":{},"ISSN":["2225-0719","2310-8819"],"issn-type":[{"value":"2225-0719","type":"print"},{"value":"2310-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,10]]}}}